Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc. was incorporated in Delaware on May 14, 2020. Prior to June 2025, Petros consisted of wholly owned subsidiaries: Metuchen Pharmaceuticals LLC, Neurotrope, Inc., Timm Medical Technologies, Inc., and Pos-T-Vac, LLC. The Company historically commercialized and developed Stendra®, a U.S. Food and Drug Administration (FDA) approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED), which it licensed from Vivus, Inc. Petros also historically marketed its own line of ED products, specifically vacuum erection device products (VEDs), through its previous subsidiaries, Timm Medical and Pos-T-Vac, including VEDs marketed as "Osbon ErecAid" and "PosTVac." In December 2024, the Company decided to discontinue sales of Stendra® to wholesalers. Beginning in March 2025, the Company is no longer involved in the commercialization, development, or sales of Stendra®. Furthermore, on June 16, 2025, the Company assigned all of the business, assets, properties, contractual rights, goodwill, going concern value, rights, and claims of Metuchen, including Metuchen's wholly-owned subsidiaries, Timm Medical and Pos-T-Vac, and their respective assets, to a special purpose vehicle managed by a third-party fiduciary for the benefit of creditors. As of June 16, 2025, this assignee succeeded to all rights, title, and interest in these assets.